Uveitis clinical trials at UCSF
4 in progress, 2 open to eligible people
Uveitis is an inflammation of the eye's middle layer. UCSF is conducting a trial to see if mindfulness can reduce anxiety in people with eye inflammation. Another trial is using advanced DNA sequencing to study eye infections.
Mindfulness Approach for Reducing Anxiety and Gloom in Ocular Inflammatory Diseases
open to eligible people ages 18 years and up
The proposed study is a block-randomized, controlled trial to evaluate the effects of a digital meditation and mindfulness practice on mental health in patients with non-infectious uveitis.
San Francisco, California
Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing
open to eligible people ages 18 years and up
This is a multi-center randomized controlled evaluator-masked trial designed to compare metagenomic deep sequencing (MDS) versus standard of care testing for improvement of outcomes for intraocular infections. Patients with presumed intraocular infections who meet the eligibility criteria will be randomized to receive MDS testing results or not to receive MDS testing results. All patients will receive standard-of-care testing to guide management. Enrolled patients will be followed at week 2, week 3-6 (randomization visit), and at 4 weeks after the randomization visit. The proportions of patients who received the appropriate therapy and the proportions of patients with improved outcome will be compared between arms. Patient quality of life, MDS performance, and the provider certainly of belief will be collected.
San Francisco, California
Adalimumab in JIA-associated Uveitis Stopping Trial
Sorry, in progress, not accepting new patients
The proposed study is a stratified, block-randomized, double-masked, controlled trial to determine the feasibility of discontinuing adalimumab treatment in patients with quiescent uveitis associated with juvenile idiopathic arthritis (JIA) or chronic anterior uveitis (CAU).
San Francisco, California and other locations
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial
Sorry, in progress, not accepting new patients
Non-infectious intermediate, posterior, and panuveitides are chronic, potentially-blinding diseases. Vision-threatening cases require long-term therapy with oral corticosteroids and immunosuppression. Based upon preliminary data, adalimumab, a fully-human, anti-TNF-α monoclonal antibody, now US FDA-approved for uveitis treatment, may be a superior corticosteroid-sparing agent than conventional immunosuppressive drugs. The ADVISE Trial is multicenter randomized, parallel-treatment, comparative effectiveness trial comparing adalimumab to conventional (small molecule) immunosuppression for corticosteroid spring in the treatment of non-infectious, intermediate, posterior, and panuveitides.
San Francisco, California and other locations
Our lead scientists for Uveitis research studies include Nisha Acharya, MD, MS Thuy Doan, MD, PhD.